{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:31:00Z","timestamp":1792521060642,"version":"4.5.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40263-025-01173-9","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T14:55:41Z","timestamp":1741964141000},"page":"473-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Update on Neuroprotection after Traumatic Brain Injury"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8539-902X","authenticated-orcid":false,"given":"Aaron M.","family":"Cook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4271-2682","authenticated-orcid":false,"given":"Morgan","family":"Michas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1675-403X","authenticated-orcid":false,"given":"Blake","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"1173_CR1","unstructured":"Centers for Disease Control. Traumatic brain injury & concussion 2024 [cited 2024 May 10]. https:\/\/www.cdc.gov\/traumaticbraininjury\/data\/index.html."},{"key":"1173_CR2","unstructured":"Centers for Disease Control and Prevention. Surveillance report of traumatic brain injury-related emergency department visits, hospitalizations, and deaths-United States, 2014 2019 [cited 2024 August 27]. https:\/\/www.cdc.gov\/traumaticbraininjury\/pdf\/TBI-Surveillance-Report-FINAL_508.pdf."},{"issue":"7","key":"1173_CR3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/11634020-000000000-00000","volume":"26","author":"KW McConeghy","year":"2012","unstructured":"McConeghy KW, Hatton J, Hughes L, Cook AM. A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury. CNS Drugs. 2012;26(7):613\u201336.","journal-title":"CNS Drugs"},{"issue":"2","key":"1173_CR4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1212\/WNL.40.2.321","volume":"40","author":"M Goldstein","year":"1990","unstructured":"Goldstein M. The decade of the brain. Neurology. 1990;40(2):321.","journal-title":"Neurology"},{"issue":"18","key":"1173_CR5","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.2174\/1381612043384060","volume":"10","author":"P Enriquez","year":"2004","unstructured":"Enriquez P, Bullock R. Molecular and cellular mechanisms in the pathophysiology of severe head injury. Curr Pharm Des. 2004;10(18):2131\u201343.","journal-title":"Curr Pharm Des"},{"issue":"5","key":"1173_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/foc.2007.22.5.2","volume":"22","author":"A Marmarou","year":"2007","unstructured":"Marmarou A. A review of progress in understanding the pathophysiology and treatment of brain edema. Neurosurg Focus. 2007;22(5):1\u201310.","journal-title":"Neurosurg Focus"},{"issue":"2","key":"1173_CR7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MCC.0b013e3280895d5c","volume":"13","author":"JW Schouten","year":"2007","unstructured":"Schouten JW. Neuroprotection in traumatic brain injury: a complex struggle against the biology of nature. Curr Opin Crit Care. 2007;13(2):134\u201342.","journal-title":"Curr Opin Crit Care"},{"issue":"4","key":"1173_CR8","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.3390\/ijms25042372","volume":"25","author":"S Silvestro","year":"2024","unstructured":"Silvestro S, Raffaele I, Quartarone A, Mazzon E. Innovative Insights into traumatic brain injuries: biomarkers and new pharmacological targets. Int J Mol Sci. 2024;25(4):2372.","journal-title":"Int J Mol Sci"},{"key":"1173_CR9","doi-asserted-by":"crossref","unstructured":"Overgaard J, Tweed WA. Cerebral circulation after head injury. 1. Cerebral blood flow and its regulation after closed head injury with emphasis on clinical correlations. J Neurosurg. 1974;41(5):531\u201341.","DOI":"10.3171\/jns.1974.41.5.0531"},{"key":"1173_CR10","doi-asserted-by":"crossref","unstructured":"White BC, Sullivan JM, DeGracia DJ, O'Neil BJ, Neumar RW, Grossman LI, et al. Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J Neurol Sci. 2000;179(S 1-2):1\u201333.","DOI":"10.1016\/S0022-510X(00)00386-5"},{"issue":"10","key":"1173_CR11","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1089\/neu.2000.17.871","volume":"17","author":"A Lewen","year":"2000","unstructured":"Lewen A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma. 2000;17(10):871\u201390.","journal-title":"J Neurotrauma"},{"issue":"3","key":"1173_CR12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/pr.109.002451","volume":"62","author":"SF Traynelis","year":"2010","unstructured":"Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62(3):405\u201396.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1173_CR13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/exnr.1999.7197","volume":"160","author":"PG Sullivan","year":"1999","unstructured":"Sullivan PG, Thompson MB, Scheff SW. Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury. Exp Neurol. 1999;160(1):226\u201334.","journal-title":"Exp Neurol"},{"issue":"4","key":"1173_CR14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/14740330903066742","volume":"8","author":"AM Cook","year":"2009","unstructured":"Cook AM, Whitlow J, Hatton J, Young AB. Cyclosporin A neuroprotection: establishing dosing guidelines for safe and effective use. Expert Opin Drug Saf. 2009;8(4):411\u20139.","journal-title":"Expert Opin Drug Saf"},{"key":"1173_CR15","unstructured":"Centers for Disease Control and Prevention. Heads up 2024 [cited 2024 January 2]. https:\/\/www.cdc.gov\/heads-up\/index.html."},{"issue":"2","key":"1173_CR16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/jcbfm.2009.203","volume":"30","author":"I Cernak","year":"2010","unstructured":"Cernak I, Noble-Haeusslein LJ. Traumatic brain injury: an overview of pathobiology with emphasis on military populations. J Cereb Blood Flow Metab. 2010;30(2):255\u201366.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"6","key":"1173_CR17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1089\/neu.2008.0748","volume":"26","author":"JB Long","year":"2009","unstructured":"Long JB, Bentley TL, Wessner KA, Cerone C, Sweeney S, Bauman RA. Blast overpressure in rats: recreating a battlefield injury in the laboratory. J Neurotrauma. 2009;26(6):827\u201340.","journal-title":"J Neurotrauma"},{"issue":"6","key":"1173_CR18","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1227\/01.NEU.0000249190.46033.94","volume":"59","author":"RA Armonda","year":"2006","unstructured":"Armonda RA, Bell RS, Vo AH, Ling G, DeGraba TJ, Crandall B, et al. Wartime traumatic cerebral vasospasm: recent review of combat casualties. Neurosurgery. 2006;59(6):1215\u201325 (discussion 25).","journal-title":"Neurosurgery"},{"issue":"5","key":"1173_CR19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJMoa072972","volume":"358","author":"CW Hoge","year":"2008","unstructured":"Hoge CW, McGurk D, Thomas JL, Cox AL, Engel CC, Castro CA. Mild traumatic brain injury in U.S. soldiers returning from Iraq. N Engl J Med. 2008;358(5):453\u201363.","journal-title":"N Engl J Med"},{"issue":"2","key":"1173_CR20","first-page":"e189","volume":"101","author":"YC Wu","year":"2023","unstructured":"Wu YC, Wen Q, Thukral R, Yang HC, Gill JM, Gao S, et al. Longitudinal associations between blood biomarkers and white matter MRI in sport-related concussion: a study of the NCAA-DoD CARE consortium. Neurology. 2023;101(2):e189\u2013201.","journal-title":"Neurology"},{"issue":"7\u20138","key":"1173_CR21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1089\/neu.2023.0419","volume":"41","author":"GJB Clarke","year":"2024","unstructured":"Clarke GJB, Skandsen T, Zetterberg H, Follestad T, Einarsen CE, Vik A, et al. Longitudinal associations between persistent post-concussion symptoms and blood biomarkers of inflammation and CNS-injury after mild traumatic brain injury. J Neurotrauma. 2024;41(7\u20138):862\u201378.","journal-title":"J Neurotrauma"},{"issue":"4","key":"1173_CR22","volume":"16","author":"H Patel","year":"2024","unstructured":"Patel H, Polam S, Joseph R. Overview of treatment options for mild traumatic brain injury: a literature review. Cureus. 2024;16(4): e59021.","journal-title":"Cureus."},{"issue":"9","key":"1173_CR23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.35804","volume":"6","author":"LL Etemad","year":"2023","unstructured":"Etemad LL, Yue JK, Barber J, Nelson LD, Bodien YG, Satris GG, et al. Longitudinal Recovery following repetitive traumatic brain injury. JAMA Netw Open. 2023;6(9): e2335804.","journal-title":"JAMA Netw Open"},{"issue":"11\u201312","key":"1173_CR24","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1089\/neu.2023.0302","volume":"41","author":"VF Lubbers","year":"2024","unstructured":"Lubbers VF, van den Hoven DJ, van der Naalt J, Jellema K, van den Brand C, Backus B. Emergency department risk factors for post-concussion syndrome after mild traumatic brain injury: a systematic review. J Neurotrauma. 2024;41(11\u201312):1253\u201370.","journal-title":"J Neurotrauma"},{"issue":"6","key":"1173_CR25","doi-asserted-by":"crossref","first-page":"E495","DOI":"10.1093\/neuros\/nyab041","volume":"88","author":"SL Zuckerman","year":"2021","unstructured":"Zuckerman SL, Yengo-Kahn AM, Tang AR, Bailes JE, Beauchamp K, Berger MS, et al. Sport-related structural brain injury and return to play: systematic review and expert insight. Neurosurgery. 2021;88(6):E495\u2013504.","journal-title":"Neurosurgery"},{"issue":"2","key":"1173_CR26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10143-017-0860-x","volume":"41","author":"MTC Poon","year":"2018","unstructured":"Poon MTC, Al-Shahi SR. Association between antithrombotic drug use before chronic subdural haematoma and outcome after drainage: a systematic review and meta-analysis. Neurosurg Rev. 2018;41(2):439\u201345.","journal-title":"Neurosurg Rev"},{"issue":"3","key":"1173_CR27","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s11357-022-00570-y","volume":"44","author":"R Weigel","year":"2022","unstructured":"Weigel R, Schilling L, Krauss JK. The pathophysiology of chronic subdural hematoma revisited: emphasis on aging processes as key factor. Geroscience. 2022;44(3):1353\u201371.","journal-title":"Geroscience."},{"issue":"6","key":"1173_CR28","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1097\/TA.0000000000003404","volume":"91","author":"MT Bounajem","year":"2021","unstructured":"Bounajem MT, Campbell RA, Denorme F, Grandhi R. Paradigms in chronic subdural hematoma pathophysiology: current treatments and new directions. J Trauma Acute Care Surg. 2021;91(6):e134\u201341.","journal-title":"J Trauma Acute Care Surg"},{"issue":"8","key":"1173_CR29","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209269","volume":"102","author":"JK Werner","year":"2024","unstructured":"Werner JK, Albrecht J, Capaldi VF, Jain S, Sun X, Mukherjee P, et al. Association of Biomarkers of neuronal injury and inflammation with insomnia trajectories after traumatic brain injury: a TRACK-TBI study. Neurology. 2024;102(8): e209269.","journal-title":"Neurology"},{"issue":"9","key":"1173_CR30","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1474-4422(22)00256-3","volume":"21","author":"FK Korley","year":"2022","unstructured":"Korley FK, Jain S, Sun X, Puccio AM, Yue JK, Gardner RC, et al. Prognostic value of day-of-injury plasma GFAP and UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients from the US TRACK-TBI cohort: an observational cohort study. Lancet Neurol. 2022;21(9):803\u201313.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1173_CR31","volume":"8","author":"KKW Wang","year":"2021","unstructured":"Wang KKW, Kobeissy FH, Shakkour Z, Tyndall JA. Thorough overview of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein as tandem biomarkers recently cleared by US Food and Drug Administration for the evaluation of intracranial injuries among patients with traumatic brain injury. Acute Med Surg. 2021;8(1): e622.","journal-title":"Acute Med Surg."},{"issue":"2","key":"1173_CR32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/14737159.2018.1428089","volume":"18","author":"KK Wang","year":"2018","unstructured":"Wang KK, Yang Z, Zhu T, Shi Y, Rubenstein R, Tyndall JA, et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn. 2018;18(2):165\u201380.","journal-title":"Expert Rev Mol Diagn"},{"issue":"6","key":"1173_CR33","first-page":"e610","volume":"95","author":"P Shahim","year":"2020","unstructured":"Shahim P, Politis A, van der Merwe A, Moore B, Chou YY, Pham DL, et al. Neurofilament light as a biomarker in traumatic brain injury. Neurology. 2020;95(6):e610\u201322.","journal-title":"Neurology"},{"issue":"10","key":"1173_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17100","volume":"17","author":"I Roberts","year":"2013","unstructured":"Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17(10):1\u201379.","journal-title":"Health Technol Assess"},{"issue":"10084","key":"1173_CR35","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(17)30638-4","volume":"389","author":"WT Collaborators","year":"2017","unstructured":"Collaborators WT. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105\u201316.","journal-title":"Lancet"},{"issue":"1","key":"1173_CR36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3171\/jns.2002.96.1.0109","volume":"96","author":"M Oertel","year":"2002","unstructured":"Oertel M, Kelly DF, McArthur D, Boscardin WJ, Glenn TC, Lee JH, et al. Progressive hemorrhage after head trauma: predictors and consequences of the evolving injury. J Neurosurg. 2002;96(1):109\u201316.","journal-title":"J Neurosurg"},{"key":"1173_CR37","doi-asserted-by":"crossref","unstructured":"Collaborators C-IBMS. Tranexamic acid in traumatic brain injury: an explanatory study nested within the CRASH-3 trial. Eur J Trauma Emerg Surg. 2021;47(1):261\u20138.","DOI":"10.1007\/s00068-020-01316-1"},{"key":"1173_CR38","doi-asserted-by":"crossref","unstructured":"Crash-trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet. 2019;394(10210):1713\u201323.","DOI":"10.1016\/S0140-6736(19)32233-0"},{"issue":"1","key":"1173_CR39","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s13054-020-03243-4","volume":"24","author":"A Brenner","year":"2020","unstructured":"Brenner A, Belli A, Chaudhri R, Coats T, Frimley L, Jamaluddin SF, et al. Understanding the neuroprotective effect of tranexamic acid: an exploratory analysis of the CRASH-3 randomised trial. Crit Care. 2020;24(1):560.","journal-title":"Crit Care"},{"key":"1173_CR40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.yfrne.2018.03.006","volume":"50","author":"CB Spani","year":"2018","unstructured":"Spani CB, Braun DJ, Van Eldik LJ. Sex-related responses after traumatic brain injury: considerations for preclinical modeling. Front Neuroendocrinol. 2018;50:52\u201366.","journal-title":"Front Neuroendocrinol"},{"issue":"7","key":"1173_CR41","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1517\/13543784.2010.489549","volume":"19","author":"DG Stein","year":"2010","unstructured":"Stein DG, Wright DW. Progesterone in the clinical treatment of acute traumatic brain injury. Expert Opin Investig Drugs. 2010;19(7):847\u201357.","journal-title":"Expert Opin Investig Drugs"},{"key":"1173_CR42","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jss.2023.11.035","volume":"295","author":"T Breeding","year":"2024","unstructured":"Breeding T, Martinez B, Katz J, Nasef H, Santos RG, Zito T, et al. The association between gender and clinical outcomes in patients with moderate to severe traumatic brain injury: a systematic review and meta-analysis. J Surg Res. 2024;295:791\u20139.","journal-title":"J Surg Res"},{"issue":"5\u20136","key":"1173_CR43","doi-asserted-by":"crossref","first-page":"e978","DOI":"10.1093\/milmed\/usab472","volume":"188","author":"N Haynes","year":"2023","unstructured":"Haynes N, Goodwin T. Literature review of sex differences in mTBI. Mil Med. 2023;188(5\u20136):e978\u201384.","journal-title":"Mil Med"},{"key":"1173_CR44","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.brainres.2013.07.014","volume":"1530","author":"ER Deutsch","year":"2013","unstructured":"Deutsch ER, Espinoza TR, Atif F, Woodall E, Kaylor J, Wright DW. Progesterone\u2019s role in neuroprotection, a review of the evidence. Brain Res. 2013;1530:82\u2013105.","journal-title":"Brain Res"},{"issue":"4","key":"1173_CR45","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.annemergmed.2006.07.932","volume":"49","author":"DW Wright","year":"2007","unstructured":"Wright DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC, et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med. 2007;49(4):391\u2013402.","journal-title":"Ann Emerg Med"},{"issue":"2","key":"1173_CR46","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1186\/cc6887","volume":"12","author":"G Xiao","year":"2008","unstructured":"Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care. 2008;12(2):R61.","journal-title":"Crit Care"},{"issue":"26","key":"1173_CR47","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa1404304","volume":"371","author":"DW Wright","year":"2014","unstructured":"Wright DW, Yeatts SD, Silbergleit R, Palesch YY, Hertzberg VS, Frankel M, et al. Very early administration of progesterone for acute traumatic brain injury. N Engl J Med. 2014;371(26):2457\u201366.","journal-title":"N Engl J Med"},{"issue":"6","key":"1173_CR48","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1161\/01.HYP.0000018041.48432.B5","volume":"39","author":"TJ Guzik","year":"2002","unstructured":"Guzik TJ, West NE, Pillai R, Taggart DP, Channon KM. Nitric oxide modulates superoxide release and peroxynitrite formation in human blood vessels. Hypertension. 2002;39(6):1088\u201394.","journal-title":"Hypertension"},{"issue":"19","key":"1173_CR49","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1089\/neu.2014.3344","volume":"31","author":"JF Stover","year":"2014","unstructured":"Stover JF, Belli A, Boret H, Bulters D, Sahuquillo J, Schmutzhard E, et al. Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized phase IIa trial (NOSTRA). J Neurotrauma. 2014;31(19):1599\u2013606.","journal-title":"J Neurotrauma"},{"issue":"Suppl 2","key":"1173_CR50","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.33588\/rn.52S02.2010787","volume":"52","author":"JJ Secades","year":"2011","unstructured":"Secades JJ. Citicoline: pharmacological and clinical review, 2010 update. Rev Neurol. 2011;52(Suppl 2):S1\u201362.","journal-title":"Rev Neurol"},{"issue":"12","key":"1173_CR51","first-page":"1757","volume":"2","author":"AV Alexandrov","year":"2001","unstructured":"Alexandrov AV. Citicoline. Ferrer international. Curr Opin Investig Drugs. 2001;2(12):1757\u201362.","journal-title":"Curr Opin Investig Drugs"},{"issue":"19","key":"1173_CR52","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2012.13256","volume":"308","author":"RD Zafonte","year":"2012","unstructured":"Zafonte RD, Bagiella E, Ansel BM, Novack TA, Friedewald WT, Hesdorffer DC, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: citicoline brain injury treatment trial (COBRIT). JAMA. 2012;308(19):1993\u20132000.","journal-title":"JAMA"},{"issue":"4","key":"1173_CR53","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3171\/JNS\/2008\/109\/10\/0699","volume":"109","author":"J Hatton","year":"2008","unstructured":"Hatton J, Rosbolt B, Empey P, Kryscio R, Young B. Dosing and safety of cyclosporine in patients with severe brain injury. J Neurosurg. 2008;109(4):699\u2013707.","journal-title":"J Neurosurg"},{"issue":"12","key":"1173_CR54","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1089\/neu.2009.1012","volume":"26","author":"AT Mazzeo","year":"2009","unstructured":"Mazzeo AT, Brophy GM, Gilman CB, Alves OL, Robles JR, Hayes RL, et al. Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial. J Neurotrauma. 2009;26(12):2195\u2013206.","journal-title":"J Neurotrauma"},{"issue":"23","key":"1173_CR55","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1089\/neu.2018.6369","volume":"36","author":"J Kelsen","year":"2019","unstructured":"Kelsen J, Karlsson M, Hansson MJ, Yang Z, Fischer W, Hugerth M, et al. Copenhagen head injury ciclosporin study: a phase IIa safety, pharmacokinetics, and biomarker study of ciclosporin in severe traumatic brain injury patients. J Neurotrauma. 2019;36(23):3253\u201363.","journal-title":"J Neurotrauma"},{"issue":"1","key":"1173_CR56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0006-8993(01)02617-8","volume":"911","author":"VL Rao","year":"2001","unstructured":"Rao VL, Dogan A, Todd KG, Bowen KK, Dempsey RJ. Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats. Brain Res. 2001;911(1):96\u2013100.","journal-title":"Brain Res"},{"issue":"1","key":"1173_CR57","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/jcph.980","volume":"58","author":"M Mokhtari","year":"2018","unstructured":"Mokhtari M, Nayeb-Aghaei H, Kouchek M, Miri MM, Goharani R, Amoozandeh A, et al. Effect of memantine on serum levels of neuron-specific enolase and on the Glasgow Coma Scale in patients with moderate traumatic brain injury. J Clin Pharmacol. 2018;58(1):42\u20137.","journal-title":"J Clin Pharmacol"},{"key":"1173_CR58","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/NDT.S186865","volume":"15","author":"F Ghaffarpasand","year":"2019","unstructured":"Ghaffarpasand F, Torabi S, Rasti A, Niakan MH, Aghabaklou S, Pakzad F, et al. Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2019;15:127\u201335.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"1173_CR59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1545968318809916","volume":"33","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chopp M, Zhang ZG, Zhang Y, Zhang L, Lu M, et al. Cerebrolysin reduces astrogliosis and axonal injury and enhances neurogenesis in rats after closed head injury. Neurorehabil Neural Repair. 2019;33(1):15\u201326.","journal-title":"Neurorehabil Neural Repair"},{"key":"1173_CR60","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.2009.05329.x","volume":"1199","author":"HS Sharma","year":"2010","unstructured":"Sharma HS, Zimmermann-Meinzingen S, Johanson CE. Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat. Ann N Y Acad Sci. 2010;1199:125\u201337.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"1173_CR61","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2174\/1871527314666150430162531","volume":"14","author":"DF Muresanu","year":"2015","unstructured":"Muresanu DF, Ciurea AV, Gorgan RM, Gheorghita E, Florian SI, Stan H, et al. A retrospective, multi-center cohort study evaluating the severity- related effects of cerebrolysin treatment on clinical outcomes in traumatic brain injury. CNS Neurol Disord Drug Targets. 2015;14(5):587\u201399.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"2","key":"1173_CR62","first-page":"281","volume":"41","author":"W Poon","year":"2020","unstructured":"Poon W, Matula C, Vos PE, Muresanu DF, von Steinbuchel N, von Wild K, et al. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind. Asian-Pacific trial Neurol Sci. 2020;41(2):281\u201393.","journal-title":"Asian-Pacific trial. Neurol Sci."},{"issue":"5","key":"1173_CR63","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/medicina58050648","volume":"58","author":"IA Muresanu","year":"2022","unstructured":"Muresanu IA, Grad DA, Muresanu DF, Hapca E, Benedek I, Jemna N, et al. The effect of cerebrolysin on anxiety, depression, and cognition in moderate and severe traumatic brain injury patients: a CAPTAIN II retrospective trial analysis. Medicina (Kaunas). 2022;58(5):648.","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"1173_CR64","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/01.WCB.0000089833.23606.7F","volume":"23","author":"TC Glenn","year":"2003","unstructured":"Glenn TC, Kelly DF, Boscardin WJ, McArthur DL, Vespa P, Oertel M, et al. Energy dysfunction as a predictor of outcome after moderate or severe head injury: indices of oxygen, glucose, and lactate metabolism. J Cereb Blood Flow Metab. 2003;23(10):1239\u201350.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"1173_CR65","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1523\/JNEUROSCI.19-01-00034.1999","volume":"19","author":"A Schurr","year":"1999","unstructured":"Schurr A, Miller JJ, Payne RS, Rigor BM. An increase in lactate output by brain tissue serves to meet the energy needs of glutamate-activated neurons. J Neurosci. 1999;19(1):34\u20139.","journal-title":"J Neurosci"},{"issue":"3","key":"1173_CR66","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.neuroscience.2007.05.002","volume":"147","author":"A Schurr","year":"2007","unstructured":"Schurr A, Payne RS. Lactate, not pyruvate, is neuronal aerobic glycolysis end product: an in vitro electrophysiological study. Neuroscience. 2007;147(3):613\u20139.","journal-title":"Neuroscience"},{"issue":"3","key":"1173_CR67","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00134-013-3203-6","volume":"40","author":"P Bouzat","year":"2014","unstructured":"Bouzat P, Sala N, Suys T, Zerlauth JB, Marques-Vidal P, Feihl F, et al. Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain. Intensive Care Med. 2014;40(3):412\u201321.","journal-title":"Intensive Care Med"},{"issue":"5","key":"1173_CR68","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3171\/jns.1999.91.5.0737","volume":"91","author":"GF Morris","year":"1999","unstructured":"Morris GF, Bullock R, Marshall SB, Marmarou A, Maas A, Marshall LF. Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators. J Neurosurg. 1999;91(5):737\u201343.","journal-title":"J Neurosurg"},{"key":"1173_CR69","doi-asserted-by":"crossref","unstructured":"Young B, Runge JW, Waxman KS, Harrington T, Wilberger J, Muizelaar JP, et al. Effects of pegorgotein on neurologic outcome of patients with severe head injury. A multicenter, randomized controlled trial. JAMA. 1996;276(7):538\u201343.","DOI":"10.1001\/jama.1996.03540070034027"},{"key":"1173_CR70","unstructured":"International Traumatic Brain Injury Research Initiative. TRACK-TBI: standard operating procedures for outcome assessment 2016 [cited 2025 January 2]. https:\/\/tracktbi.ucsf.edu\/sites\/tracktbi.ucsf.edu\/files\/Outcome%20Assessment%20SOP_edits%20for%20public%20posting.pdf."},{"issue":"5","key":"1173_CR71","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1213\/ANE.0000000000006503","volume":"137","author":"C Trieu","year":"2023","unstructured":"Trieu C, Rajagopalan S, Kofke WA, Cruz NJ. Overview of hypothermia, its role in neuroprotection, and the application of prophylactic hypothermia in traumatic brain injury. Anesth Analg. 2023;137(5):953\u201362.","journal-title":"Anesth Analg"},{"key":"1173_CR72","unstructured":"NeuroVive\u2019s NeuroSTAT project receives FDA fast track designation [press release]. July 27, 2019."},{"issue":"6","key":"1173_CR73","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1007\/s13311-023-01414-z","volume":"20","author":"MJ Hansson","year":"2023","unstructured":"Hansson MJ, Elmer E. Cyclosporine as therapy for traumatic brain injury. Neurotherapeutics. 2023;20(6):1482\u201395.","journal-title":"Neurotherapeutics"},{"key":"1173_CR74","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00006123-199908000-00001","volume":"45","author":"MR Bullock","year":"1999","unstructured":"Bullock MR, Lyeth BG, Muizelaar JP. Current status of neuroprotection trials for traumatic brain injury: lessons from animal models and clinical studies. Neurosurgery. 1999;45:207\u201320.","journal-title":"Neurosurgery"},{"issue":"1","key":"1173_CR75","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12974-023-02734-9","volume":"20","author":"BR Lins","year":"2023","unstructured":"Lins BR, Anyaegbu CC, Hellewell SC, Papini M, McGonigle T, De Prato L, et al. Cannabinoids in traumatic brain injury and related neuropathologies: preclinical and clinical research on endogenous, plant-derived, and synthetic compounds. J Neuroinflamm. 2023;20(1):77.","journal-title":"J Neuroinflamm"},{"issue":"1","key":"1173_CR76","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","volume":"16","author":"L Cristino","year":"2020","unstructured":"Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2020;16(1):9\u201329.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"1173_CR77","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.nbd.2005.11.004","volume":"22","author":"D Panikashvili","year":"2006","unstructured":"Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, et al. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis. 2006;22(2):257\u201364.","journal-title":"Neurobiol Dis"},{"key":"1173_CR78","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(05)70253-2","volume":"5","author":"AI Maas","year":"2006","unstructured":"Maas AI, Murray G, Henney H III, Kassem N, Legrand V, Mangelus M, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 2006;5:38\u201345.","journal-title":"Lancet Neurol"},{"issue":"9","key":"1173_CR79","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1102609","volume":"366","author":"JT Giacino","year":"2012","unstructured":"Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012;366(9):819\u201326.","journal-title":"N Engl J Med"},{"key":"1173_CR80","unstructured":"Shinkei Therapeutics Inc. Study to assess the safety of amantadine hydrochloride (HCl) intravenous (IV) solution (MR-301) in patients with severe traumatic brain injury (TBI). 2024 [updated 10\/24\/2024]. https:\/\/clinicaltrials.gov\/study\/NCT06253923?intr=amantadine&cond=TBI-Traumatic%20Brain%20Injury&rank=2."},{"issue":"2","key":"1173_CR81","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-020-01431-8","volume":"81","author":"J Chun","year":"2021","unstructured":"Chun J, Giovannoni G, Hunter SF. Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects. Drugs. 2021;81(2):207\u201331.","journal-title":"Drugs"},{"key":"1173_CR82","unstructured":"Abalonex L. Safety and efficacy of ABX-101 in participants aged 18 to 50 years of age with moderate to severe traumatic brain injury 2023 [updated 10\/23\/2023]. https:\/\/clinicaltrials.gov\/study\/NCT06096415?intr=abx101&rank=1."},{"issue":"27","key":"1173_CR83","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1056\/NEJMoa2020473","volume":"383","author":"PJ Hutchinson","year":"2020","unstructured":"Hutchinson PJ, Edlmann E, Bulters D, Zolnourian A, Holton P, Suttner N, et al. Trial of dexamethasone for chronic subdural hematoma. N Engl J Med. 2020;383(27):2616\u201327.","journal-title":"N Engl J Med"},{"key":"1173_CR84","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.wneu.2024.05.069","volume":"188","author":"GA Monteiro","year":"2024","unstructured":"Monteiro GA, Queiroz TS, Goncalves OR, Cavalcante-Neto JF, Batista S, Rabelo NN, et al. Efficacy and safety of atorvastatin for chronic subdural hematoma: an updated systematic review and meta-analysis. World Neurosurg. 2024;188:177\u201384.","journal-title":"World Neurosurg."},{"issue":"1","key":"1173_CR85","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13063-021-05907-0","volume":"23","author":"S Immenga","year":"2022","unstructured":"Immenga S, Lodewijkx R, Roos Y, Middeldorp S, Majoie C, Willems HC, et al. Tranexamic acid to prevent operation in chronic subdural haematoma (TORCH): study protocol for a randomised placebo-controlled clinical trial. Trials. 2022;23(1):56.","journal-title":"Trials"},{"issue":"2","key":"1173_CR86","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12028-013-9951-x","volume":"21","author":"JA Radic","year":"2014","unstructured":"Radic JA, Chou SH, Du R, Lee JW. Levetiracetam versus phenytoin: a comparison of efficacy of seizure prophylaxis and adverse event risk following acute or subacute subdural hematoma diagnosis. Neurocrit Care. 2014;21(2):228\u201337.","journal-title":"Neurocrit Care"},{"issue":"3","key":"1173_CR87","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/ane.13131","volume":"140","author":"SY Won","year":"2019","unstructured":"Won SY, Dubinski D, Sautter L, Hattingen E, Seifert V, Rosenow F, et al. Seizure and status epilepticus in chronic subdural hematoma. Acta Neurol Scand. 2019;140(3):194\u2013203.","journal-title":"Acta Neurol Scand"},{"key":"1173_CR88","doi-asserted-by":"crossref","first-page":"1190878","DOI":"10.3389\/fneur.2023.1190878","volume":"14","author":"L Wu","year":"2023","unstructured":"Wu L, Guo X, Ou Y, Yu X, Zhu B, Li Y, et al. Seizure after chronic subdural hematoma evacuation: associated factors and effect on clinical outcome. Front Neurol. 2023;14:1190878.","journal-title":"Front Neurol"},{"issue":"6","key":"1173_CR89","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1089\/neu.2015.4131","volume":"33","author":"M Browning","year":"2016","unstructured":"Browning M, Shear DA, Bramlett HM, Dixon CE, Mondello S, Schmid KE, et al. Levetiracetam treatment in traumatic brain injury: operation brain trauma therapy. J Neurotrauma. 2016;33(6):581\u201394.","journal-title":"J Neurotrauma"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01173-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01173-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01173-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:17:38Z","timestamp":1744204658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01173-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":89,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1173"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01173-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"17 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No funding supported the writing or submission of this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors report no pertinent conflicts of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Idea origination\u2014A.C.; outline creation\/revision\u2014B.R., M.M., and A.C.; literature search\/data analysis\u2014B.R., M.M., and A.C.; drafted manuscript\u2014B.R., M.M., and A.C.; critically revised manuscript\u2014B.R., M.M., and A.C.; all authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}